Mirum Pharmaceuticals, Inc.·4

Mar 17, 7:30 PM ET

Howe Jolanda 4

4 · Mirum Pharmaceuticals, Inc. · Filed Mar 17, 2026

Research Summary

AI-generated summary of this filing

Updated

Mirum (MIRM) SVP Jolanda Howe Sells Shares After Exercising RSUs

What Happened
Jolanda Howe, SVP and Global Controller of Mirum Pharmaceuticals (MIRM), had performance restricted stock units (PRSUs) convert/vest on March 15, 2026 and then sold shares the following day. The Form 4 shows conversions/exercises (derivative transactions) of PRSUs for 2,658 and 6,000 shares on March 15, 2026, and an open-market sale of 4,732 shares on March 16, 2026 at $91.98 per share, yielding $435,239. Footnotes indicate some shares were sold to cover tax withholding tied to the vesting.

Key Details

  • Transaction dates: March 15, 2026 (conversion/vesting of PRSUs) and March 16, 2026 (open-market sale).
  • Sale: 4,732 shares sold on 2026-03-16 at $91.98 — total proceeds $435,239.
  • Derivative/vesting: conversion/exercise entries for 2,658 and 6,000 PRSUs on 2026-03-15 (reported as derivative transactions).
  • Tax withholding: filing notes shares were sold to cover tax withholding obligations associated with the vesting.
  • Vesting schedules (per footnotes): one grant vested 2/3 on 3/15/2025 and 1/3 on 3/15/2026; another vests 2/3 on 3/15/2026 and 1/3 on 3/15/2027.
  • Shares owned after transaction: not specified in the provided filing excerpt.
  • Filing timeliness: Form filed 2026-03-17 for transactions on 2026-03-15 (no late filing indicated).

Context
This was a conversion/vesting of performance RSUs followed by an open-market sale — common for covering tax withholding and realizing proceeds from vested equity. The filing shows a sale rather than a new purchase, so it’s generally a routine liquidity event rather than a fresh insider buy signal.

Insider Transaction Report

Form 4
Period: 2026-03-15
Howe Jolanda
SVP, GLOBAL CONTROLLER
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-03-15+2,6587,161 total
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-03-15+6,00013,161 total
  • Sale

    Common Stock

    [F2]
    2026-03-16$91.98/sh4,732$435,2398,429 total
  • Exercise/Conversion

    Performance Restricted Stock Units

    [F1][F3]
    2026-03-152,6580 total
    Common Stock (2,658 underlying)
  • Exercise/Conversion

    Performance Restricted Stock Units

    [F1][F4]
    2026-03-156,0003,000 total
    Common Stock (6,000 underlying)
Footnotes (4)
  • [F1]Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
  • [F2]Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units.
  • [F3]The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026.
  • [F4]The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.
Signature
/s/ Judit Ryvkin, Attorney-in-Fact|2026-03-17

Documents

2 files